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Abstract
Neoteric advances in genetics make it possible to define genetic risk in cancer, and there should
be methods in place to provide comprehensive genomic care with oncology advanced practice
registered nurses bridging this gap. The current scope of nursing practice stipulates genetic and
genomic literacy; however, there remains a deficit among advanced practice registered nurses in
identifying and addressing psychosocial distress during the genetic cancer risk assessment
process. Oncology advanced practice registered nurses must be equipped with the knowledge
that the genetic cancer risk assessment also involves protecting patients from the psychosocial
repercussions of carrying a hereditary cancer gene beyond medical assessment. The goals of this
study were to identify psychosocial risk factors in individuals with heightened cancer risk,
improve psychosocial management plans, increase shared decision-making referrals based on
individual risk factors, and determine the appropriate psychosocial risk tool to utilize in clinical
practice. The Genetic Psychosocial Risk Instrument and Supportive Care Screening
Questionnaire were implemented in utilizing best practice guidelines at an outpatient community
oncology practice in San Antonio, Texas. This three-month project used a quantitative
comparative design with a randomized convenience sample who received the Genetic
Psychosocial Risk Instrument or Supportive Care Screening Questionnaire. The reconceptualized
uncertainty of illness theory was the theoretical framework used to guide this project.
Discovering the antecedents of uncertainty provided the advanced practice registered nurses with
salient clues about the patient’s uncertainty related to the genetic cancer risk assessment process
and helped prompt psychosocial referrals. Results revealed that in patients undergoing genetic
cancer risk assessment assessments, a certain percentage experienced psychosocial distress, and
there is demand for a standardized psychosocial needs identification in this patient population.
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Chapter 1: Introduction
Recent breakthroughs in genetics have made it feasible to explicate the hereditary risk of
some diseases, especially cancer. Increasing access to genetic testing allows health practitioners
to identify individuals who have a heightened risk of developing cancer, which prompts genetic
cancer risk assessments (GCRA), improves surveillance management, and promotes an
awareness of novel targets such as pharmacogenetics in patients who already have a cancer
diagnosis. Regardless of the benefits of genetic testing, individuals at high risk for serious illness
may become increasingly fearful or distressed about the future (Esplen et al., 2013). Previvors
are individuals with a genetic predisposition to develop cancer but as yet have not been
diagnosed (Dean & Davidson, 2018). Although genetic testing can decrease a previvor’s worries
about whether they have a high genetic cancer risk, testing positive often produces negative
emotions and long-term uncertainty, thus requiring uncertainty management. Evidence suggests
that interest in pursuing genetic testing for cancer syndromes is high, with some reports
indicating an 80–90% uptake rate (American Cancer Society, 2020).
Even though resources exist to deliver effective services to those with psychosocial needs
in clinical practice, mechanisms are needed to help identify high-risk hereditary cancer patients
with psychosocial health needs and link them to appropriate services (Riba et al., 2019).
Therefore, it is important to choose tools that are sensitive to evaluate the efficacy of the
intervention on psychosocial concerns in high-risk patients undergoing GCRA. The purpose of
this study was to compare the Genetic Psychosocial Risk Instrument (GPRI) and the Supportive
Care Screening Questionnaire (SCSQ) in their ability to evaluate psychosocial concerns and
prompt psychosocial referrals during the GCRA process. There is limited data available;
however, with respect to comparing the responsiveness of these two instruments and no
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consensus as to which one is superior because no “gold standard” currently exists for
psychosocial measurement in high-risk individuals undergoing genetic testing. The GPRI tool
has been shown beneficial in determining whether patients need additional psychosocial support
in the wake of genetic testing (Esplen et al., 2013). The SCSQ, referenced from the Edmonton
Symptom Assessment Scale (ESAS) and Patient Health Questionnaire-2 (PHQ2), is currently
utilized in primary investigators’ clinical practices but only in patients with a cancer diagnosis.
Statement of the Problem
This evidence-based, scholarly project was designed to identify high-risk individuals
undergoing hereditary cancer screening who are liable to experience significant difficulty
adjusting to the genetic information and identify high-risk individuals who might benefit from
preventative interventions to contain their distress level. Oncology advanced practice registered
nurses (APRNs) need to understand that GCRA involves protecting patients from the
psychosocial repercussions of carrying a hereditary cancer gene beyond medical assessment. As
a result, this project is unique as there are currently no studies investigating the psychosocial
impact of GCRA screening by APRNs in the outpatient community setting.
According to the National Cancer Institute, approximately 5–10% of newly diagnosed
cancers are genetically inherited (National Cancer Institute [NCI], 2016), and although these
statistics are not high, the magnitude of risk conferred by cancer susceptibility genes is often
dramatic (Weitzel, 1999). Counseling before and after genetic testing is an integral part of the
process to discuss the rationale for any genetic testing, disclose results, define other cancer risks,
identify educational needs, and secure referrals, if necessary, for ongoing management
(American College of Obstetricians and Gynecologists [ACOG], 2019). What is critical and
missing in the GCRA process is the assessment of these high-risk individuals’ psychosocial
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concerns. Currently, there is no standardized psychosocial screening template for high-risk
individuals undergoing GCRA in my clinical practice.
The negative psychosocial impact of genetic testing includes distress (Gritz et al., 2005),
more specifically, distress associated with pressure to inform family members of a mutation they
may share and isolation from other family members (McInerney-Leo et al., 2005). In addition,
other psychosocial impacts might include survivor’s guilt if found not to carry the mutation,
depression, anxiety disorders, and cancer-related worries after receiving positive mutation results
(van Dijk et al., 2006). Qualitatively oriented studies have identified several emotional responses
to testing, including sadness, relief, anxiety, and guilt (Cella et al., 2002). Early identification of
high-risk individuals who are potentially at higher risk of suffering distress and adverse
psychological effects during the GCRA process makes it possible to allocate valuable
psychosocial resources (Maheu et al., 2018). In most oncology settings, there are no accepted
ways to assess the situation-specific psychosocial concerns in high-risk individuals that have
been noted empirically (Cella et al., 2002). Many of these high-risk individuals are often left
grappling and dealing with their psychosocial issues alone, leading to nonadherence to treatment
or surveillance regimens. This evidence-based project aimed to enhance preventative health
delivery in high-risk individuals undergoing GCRA, identify individuals who needed
psychosocial interventions, and provide additional psychosocial support as warranted.
Oncology is one of the first subspecialties to experience the full impact of the genomics
revolution, and it is now possible to use genomic science in prevention, screening, diagnostics,
prognostics, treatment selection, and monitoring (Mahon, 2017). The National Comprehensive
Cancer Network (National Comprehensive Cancer Network [NCCN], 2019) advocated for
clinical practice guidelines in oncology to include distress management. Psychological
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impairments related to the genetic GCRA process can also lead to substantial social problems,
such as the inability to work or fulfill other normative social roles (Adler & Page, 2008). For
these reasons, the Institute of Medicine mandated that a quality cancer care program must
integrate the psychosocial needs in routine cancer care and state that “all cancer care should
ensure the provision of appropriate psychosocial health services by identifying each patient’s
psychosocial health needs and design and implement a plan that links the patient with needed
psychosocial care” (Adler & Page, 2008, p. 219). In ensuring centered patient care, the American
College of Surgeons (American College of Surgeons [ACoS], 2012) initiated an accreditation
standard requiring cancer centers to have an onsite psychosocial program to identify patients and
refer them for appropriate care. Nurses have long been aware of the intersection of heredity,
lifestyle, and the environment in their assessments of patients and families (Kerber & Ledbetter,
2017). The Oncology Nursing Society (ONS) advocates that part of the APRNs role is to provide
genetic and genomic care to individuals in conjunction with expert providers (Mahon, 2017).
During the pretesting phase of the hereditary cancer process, APRNs trained in genetics help
evaluate risk assessment based on personal and family history, select the best testing strategy and
laboratory, and provide research study options. In the postesting phase, the APRN interprets test
results, provides recommendations for follow-up, and coordinates appropriate care for other
family members.
Purpose of the Study
The overall aim of this Doctor of Nursing Practice (DNP) quality improvement project
was to improve psychosocial screening practices, implement and compare two psychosocial
screening tools to help identify psychosocial concerns, and increase psychosocial referrals in
high-risk individuals undergoing genetic testing at a community outpatient oncology clinic in
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Texas. This project had the potential to address the gap between recommendations of available
evidence-based literature for best practices. With the advent of APRNs running high-risk cancer
clinics, more APRNs are completing specialized training in GCRA, and currently, there is no
routine psychosocial screening assessment being conducted during these GCRA visits. Early
identification of psychosocial concerns is crucial to developing individualized treatments to
improve psychosocial function (Thomas et al., 2019), enhancing preventative health delivery,
and impacting cancer morbidity and mortality rates as these high-risk individuals are mode adept
in following their treatment or surveillance regimens as prescribed. The American Society of
Clinical Oncology’s (ASCO) 2003 (as cited in Lu et al., 2014) policy statement on genetic
testing recommends testing under three conditions: the patient has a personal history suggesting
genetic susceptibility, the test can be adequately interpreted, and test results will influence
medical decision-making. To emphasize the importance of counseling, ASCO experts also
recommended that testing “only be done in the setting of pre- and posttest counseling (Lu et al.,
2014). In this project, I identified psychosocial issues and referrals were made during the
pretesting counseling phase of the genetic testing process.
Integral to meeting triple aim initiative goals is aligning incentives for high-risk
individuals undergoing GCRA, where the emphasis is on effectively managing and improving
individual and population care. The ability to identify the individuals for whom more increased
cancer surveillance is warranted may significantly reduce mortality from hereditary cancer
syndromes, enable earlier diagnosis, drive treatment choices, and provide aggressive surveillance
and prevention. In many cases, these early interventions can significantly reduce human
suffering and health care costs (Moore & DeBuono, 2013). Per recommendations from the
Institute of Medicine (IOM, as cited in Adler & Page, 2008), ACoS, ASCO, ONS, and NCCN,
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the project’s objectives included (a) implementing psychosocial screenings with the use of GPRI
or SCSQ in high-risk hereditary individuals who presented for GCRA, (b) comparing the number
of referrals elicited by both screening tools and choosing a psychosocial screening tool to be
utilized during the GCRA process by oncology APRNs in clinical practice, and (c) increasing the
number of psychosocial referrals in high-risk patients undergoing GCRA. Data collected from
the GPRI and the SCSQ was analyzed inductively to understand better the patient’s psychosocial
well-being during the GCRA process at a community outpatient cancer care clinic in San
Antonio, Texas.
Research Question
This project’s primary concern was to implement and evaluate whether the Genetic
Psychosocial Risk Instrument (GPRI) or the Supportive Care Screening Questionnaire (SCSQ)
could help identify the psychosocial status of high-risk individuals undergoing genetic cancer
risk assessments (GCRA) to ascertain which tool was more appropriate in prompting necessary
psychosocial referrals. The PICO question was: For APRNs in the oncology setting who provide
genetic cancer risk assessments, does the use of the GPRI tool compared to the SCSQ identify
psychosocial concerns and prompt psychosocial referrals in high-risk individuals undergoing
hereditary cancer screening?
•

P: high-risk hereditary cancer patients

•

I: use of the GPRI

•

C: use of the SCSQ

•

O: identify psychosocial needs and increase the number of psychosocial referrals

High-risk hereditary individuals were defined as adult individuals diagnosed with cancer,
primarily breast, ovarian, colorectal, pancreatic, gastric, prostate, and melanoma cancers.
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Individuals who have had multiple cancers occur in the same individual or have had cancer
develop in paired organs (both breasts, both ovaries, both kidneys) are also high-risk (Stanislaw
et al., 2016). Previvors who have family histories of these cancers, in either first-degree or
second-degree relatives, or patients diagnosed with cancer before the age of 50, were also
considered high-risk. Individuals with first-degree relatives with known cancer mutations and
those who have had multiple individuals in a family who had the same type of cancer were also
considered high-risk.
The Genetic Psychosocial Risk Instrument (GPRI) is a brief tool that is reliable and a
valid instrument created to screen the psychosocial risk among adults undergoing genetic testing.
The GPRI screening tool is designed for genetic testing services and is used to guide clinicians
about which patients would benefit from added psychosocial support during the genetic testing
process (Esplen et al., 2013). This tool has been validated as a psychological screening
instrument for the genetic testing field. Most of the existing psychological screening tools do not
consider the risk factors associated with heritable illness or genetic-related stressors (Esplen et
al., 2013).
The Supportive Care Screening Questionnaire (SCSQ) is currently utilized at the
researcher’s clinical site to screen for distress only in patients with an existing cancer diagnosis.
The SCSQ is a reliable and validated distress assessment tool that measures the psychometric
properties of anger, loss of control, fear, and anxiety, and it pulls its reference from the ESAS
and PHQ2 (Maamoun et al., 2013). My clinical site did not offer any psychosocial screening in
patients undergoing GCRA. The study’s three-month time frame was calculated based on having
30 study participants for the project, given that I typically saw one to three new genetic patients a
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week. In three months, there were enough patients enrolled in this evidence-based project to
meet the study goals.
Definition of Key Terms
Advanced practice registered nurses. A group of professionals, including nurse
practitioners, who treat and diagnose illnesses, advise the public on health issues, manage
chronic disease, and engage in continuous education to remain ahead of technological,
methodological, or other developments in the field (American Nurses Association, 2020).
Comprehensive cancer risk assessment. A consultative service that includes clinical
assessment, genetic testing when appropriate, and risk management recommendations delivered
in one or more genetic counseling sessions (NCI, n.d.).
Genetic Psychosocial Risk Instrument. An instrument used to screen for psychosocial
risk in individuals undergoing genetic testing for adult-onset hereditary disease (Esplen et al.,
2013).
Hereditary cancer syndromes. These are gene changes or mutations that can be passed
down from parent to child and increase a person’s risk of developing cancer (University of Texas
MD Anderson Cancer Center, n.d.).
Previvors. These are individuals with a genetic predisposition to develop cancer who
may or may not have been tested for genetic predisposition or diagnosed with cancer (Dean &
Davidson, 2018).
Psychosocial distress. This is a broad term that describes acute mental stress resulting
from life circumstances or mental illness. Levels of distress are measured based on the severity
of the symptoms and their impact on their daily lives (Jacob, 2013).

9
Supportive Care Screening Questionnaire. A tool designed after pilot testing at Texas
Oncology to measure distress and unmet needs in the adult oncology population. It combines a
patient’s need assessment and the ESAS tool (Texas Oncology, 2020).
Conclusion
The current scope of nursing practice stipulates genetic and genomic literacy; however,
there remains a deficit among APRNs identifying and addressing psychosocial distress during
GCRA. Despite NCCN guidelines requiring all patients in the oncology setting receive a
psychosocial risk assessment, high-risk individuals needing GCRA are not typically assessed.
The literature review will reveal that the psychosocial impact of GCRA includes pressure,
isolation, survivors’ guilt, depression, anxiety, sadness, and cancer-related worries. These
psychosocial problems can contribute to poorer adherence, functional impairment, and adverse
medical outcomes. Acknowledging the psychosocial issues presented during the GCRA process
and assisting patients in getting the help they need is paramount in improving the quality of care
and providing comprehensive cancer care.
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Chapter 2: Literature Review
This chapter was intended to provide a review of the literature used to guide this practice
change project and allot evidence-based support to investigate the problem statement related to
the project: Increasing psychosocial assessments in high-risk patients undergoing hereditary
cancer screening. The PICO question was: For APRNs in the oncology setting who provide
genetic cancer risk assessments, does the use of the GPRI tool compared to the SCSQ identify
psychosocial concerns and prompt psychosocial referrals in high-risk individuals undergoing
hereditary cancer screening? This study utilized an evidence-based approach to investigate
whether the use of the GPRI compared to the SCSQ by APRNs in the oncology setting helped
identify high-risk patients with psychosocial issues. The reporting aimed to prompt clinicians to
address these patients’ psychosocial issues and employ appropriate clinical interventions, which
promoted better clinical outcomes.
Literature Search Methods
A search was conducted to find the highest evidence studies related to the PICO question
utilizing meta-analysis, systematic reviews, and randomized clinical trials based on the
established criteria. Keywords used to organize the search included Genetic Psychosocial Risk
Instruments, risk assessments in cancer and psychosocial state, identifying the psychosocial state
in high-risk cancer patients, APRNs role in genetic cancer risk assessments, hereditary cancer
syndromes and screening, cancer prevention, psychological distress in genetic screenings,
psychological factors related to genetic testing, coping styles in cancer-related threats,
uncertainty in hereditary cancer screening, unmet support needs in hereditary cancer screening,
cancer genetic risk assessments and distress, and advanced practice nurses and genetic testing.
The leading search engines used were PubMed, Cochrane, Google Scholar, and CINAHL.
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Current literature within the past 10 years (2010–2020) was sought unless the content included
classic works related to conceptual frameworks. Furthermore, exceptions to the 10-year
exclusion were limited to meaningful works that provided crucial background information.
Theoretical Framework
The theoretical framework for this study utilized the reconceptualized uncertainty of
illness theory (RUIT) because uncertainty is still recognized as a fundamental construct in
studying the patients’ responses to coping with genetic testing (Tluczek et al., 2010). Mishel
(1988) designed this middle-range theory and defined uncertainty as the “inability to determine
the meaning of illness-related events which occurs in situations where the decision-maker is
unable to assign definite values to objects and events and cannot accurately predict outcomes
because sufficient cues are lacking” (p. 225). Uncertainty can motivate or be a barrier to
pursuing genomic cancer testing. Appraisal of uncertainty influences the patient experience of
uncertainty, the outcome of uncertainty for patients, and the coping strategies utilized (Bartley et
al., 2020), which are critical during the genetic testing process. Mishel’s (1990) RUIT furnished
us with a theoretical framework explaining how uncertainty is generated and how it affects
psychological adjustment to illness (Zhang, 2017). According to Dean and Fisher (2019), the
theoretical features of RUIT are pertinent to understanding how uncertainty informs previvors’
cancer risk management. The features include:
a. The nature of uncertainty (e.g., sources and antecedents).
b. Appraisals or assessments (and emotional responses) of the uncertainty.
c. Strategies or coping approaches to manage uncertainty (Dean & Fisher, 2019).
The RUIT model clearly indicates these features, as shown in Figure 1, displaying the concepts
and their relationships, which form the basis for the theoretical and empirical material.
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Figure 1
Antecedents and Outcomes of the Reconceptualized Uncertainty in Illness Theory

Note. Adapted from “The Illness Uncertainty Concept: A Review,” by L. J. Wright, N. Afari, &
A. Zautra, 2009, Current Pain and Headache Reports, 13(2), p. 134
(https://doi.org/10.1007/s11916-009-0023-z). Copyright © 2009, Current Medicine Group.
Uncertainty in the hereditary cancer screening process can arise when patients
contemplate their results, have prospective prophylactic procedures that are recommended if
found to have a positive mutation, need subsequent treatments, provided survival chances, and
have to relay positive mutations to other close family members. Assessing psychosocial risk
during this period of uncertainty is crucial as it helps patients receive appropriate services and
help them during this challenging process. The emotional experiences of individuals who receive
genetic test results indicating a variant of uncertain clinical significance (a change in the genetic
sequence with unknown cancer risks) may be even more complex (Hamilton & Robson, 2019).
Bartley et al. (2020) noted that participants who received uncertain genomic results experienced
a range of affective reactions to their results, including frustration, shock, regret, sadness,
disappointment, and further uncertainty about the future. Patients’ uncertainty about management
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strategies may be to maintain, increase, reduce, or adjust to that uncertainty (Brashers, 2007).
Research informed by RUIT suggested that patients appraising uncertainty as a danger will
experience negative emotions and poor health outcomes (Clayton et al., 2018; Kang, 2006),
whereas patients appraising uncertainty as an opportunity are likely to self-reflect on the
situation and even restructure one’s life and priorities. These appraisals inform their uncertainty
management decisions (Mishel, 1990; Mishel & Clayton, 2008).
There is a need for nurses to be intricately involved in cancer genetics by targeting their
efforts to understand the effect of uncertainty on patient care through teaching (Wallace, 2003).
Uncertainty associated with a lack of knowledge about genetic counseling can create barriers to
important screening behaviors. Advanced practice registered nurses who provide genetic cancer
risk assessments (GCRA) can be instrumental in educating high-risk individuals about the
importance, risks, and benefits of adhering to recommendations after testing and should be able
to identify and address any psychosocial concerns that can limit adherence. This theoretical
framework was chosen for the project because, in oncology, the degree of uncertainty of
developing cancer in high-risk individuals is exceptionally high at pretesting because patients
often grapple to perceive and understand their chances of developing cancer, especially if they
have high-risk hereditary features. The “fear of the unknown” is a significant driving factor in
the level of uncertainty before genetic counseling and testing and during the waiting period for
results to come in. Mishel’s (1990) reconceptualized uncertainty in illness theory suggests that
uncertainty evolves, stating that the longer a patient lives with a chronic illness and continual
uncertainty, the more positively they appraise their uncertainty. The appraisal of uncertainty as
opportunity or danger is supported by RUIT, which states that the experience of uncertainty is
neutral until the implications of uncertainty are determined by the patient (Mishel, 1990, p. 258).
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Historical Overview
The ultimate goal of hereditary cancer screening is to reduce cancer mortality in
individuals with genetic mutations by increasing screening and diagnostic interventions and
paving the way for more tailored treatment plans in those who already have cancer. Though most
individuals report satisfaction with gaining genetic information about themselves, negative
affective consequences, such as anxiety, shock, guilt, and depression, have been reported for
those identified as carriers (Evers-Kiebooms et al., 1994; Harris et al., 1996; Jung et al., 1994).
Anxiety both during the GCRA visit and immediately after receiving positive carrier results has
been reported (Bekker et al., 1994; Harris et al., 1996; Mennie et al., 1993). Although learning
one’s testing results may promote disease prevention efforts, health experts have expressed
concern about potential adverse emotional, cognitive, and behavioral consequences of such
knowledge (Lerman & Croyle, 1996; Lerman & Schwartz, 1993). Qualitatively oriented studies
have identified several emotional responses to testing, including sadness, depression, relief,
anxiety, and guilt (Biesecker et al., 1993). A threat of a genetic condition can elicit feelings and
reactions that change family and intimate relations, decisions concerning childbearing and
prophylactic surgery, perception of body image, self-esteem, and quality of life (Hutson, 2003).
A study of patients with colorectal cancer undergoing genetic testing for hereditary
nonpolyposis colorectal cancer (HNPCC) indicated that the prevalence of depressive symptoms
was 24%, as measured on the Center for Epidemiologic Studies Depression Scale (Vernon et al.,
1997). The underlying levels of psychological distress in previvors and cancer patients
undergoing hereditary cancer screening have been dramatically underestimated, as generalized
by Pasacreta (2003), who summarized that available literature challenges a common notion that
only individuals with a positive test result will need psychosocial services. Breast cancer patients
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diagnosed less than one year ago demonstrated more cancer-specific intrusive thoughts before
counseling. This group also had more genetic testing-specific intrusive thoughts before DNA test
disclosure (van Roosmalen et al., 2003). It also appeared that women with children and the first
family member to pursue genetic testing were more likely to be distressed. In Arver et al.’s
(2004) study, there also tended to be higher levels of psychological distress over time in
noncarriers than carriers. Cancer-specific distress was found in African American women
undergoing BRCA (BReast CAncer gene) counseling and testing, and this distress was elevated
with counseling participation regardless of testing participation (Thompson et al., 2002). Studies
on previvors from high‐risk cancer families who seek cancer genetic testing but are ineligible for
it still have high levels of anxiety associated with the hereditary screening process (Meiser,
2005).
Psychosocial Screening in High-Risk Individuals
Assessing the psychosocial impact often provides clues about how the counselee and
family may understand and cope with disclosing genetic testing information (Edwards et al.,
2008; Pieterse et al., 2005; Pieterse et al., 2007). Individual coping styles, concern for other
family members, high levels of distress before testing, a history of depression, having lost a
relative to hereditary cancer, and having young children can all affect how well individuals cope
with the information they receive after genetic testing (Lodder et al., 2001; Ritvo et al., 1999;
van Oostrom et al., 2003; Wang et al., 2005). Research has shown that distress levels after
receiving genetic test results depended on the coping style and not just on the positive or
negative gene status; however, a prior cancer diagnosis experience can enhance the coping
abilities of mutation carriers (Hallowell et al., 2004; Meiser et al., 2002; Tercyak et al., 2001).
The researchers noted the need for future nursing research to help identify specific psychosocial
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needs among different family members and specific psychosocial needs associated with different
types of hereditary cancer syndromes. Other studies, however, have reported no differences in
distress level between carriers and noncarriers, as highlighted in a study by Kinney et al. (2005),
who noted that the hypothesis that mutation carriers, particularly women who had no personal
history of breast carcinoma, were expected to report higher distress than noncarriers was not
supported.
A systematic review of controlled trials and prospective studies examining the impact of
genetic counseling for breast, ovarian, and colorectal cancer on a more comprehensive range of
cognitive, affective, and behavioral outcomes disputed the notion that genetic counseling could
lead to adverse psychological sequela (Braithwaite et al., 2006). The increased risk of developing
cancer associated with positive genetic testing results may be experienced as traumatic by many
patients. However, not all individuals with positive genetic testing results will experience
increased distress, and studies should consider specific risk factors to select those who are more
likely to need psychological support (Lombardi et al., 2019). Individuals at high risk for gastric
cancer perceived a very high personal risk of cancer but reported low cancer worry levels. This
paradoxical result may be attributed to participants’ high levels of confidence in the effectiveness
of screening. These findings highlight the importance for clinicians to discuss realistic risk
appraisals and expectations toward screening with unaffected families at risk for gastric cancer to
help mitigate anxiety and help with coping (Li et al., 2016).
Several studies have shown that counselees do not experience psychopathological levels
of distress after DNA test result disclosure; however, it has not systematically been studied
whether the absence of psychopathology also means that counselees do not want to receive help
(Vos et al., 2013). In general, genetic counseling for cancer does not have serious adverse
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psychological effects, but approximately 25% of counselees experience heightened levels of
anxiety, depression, and distress during or after counseling (Eijzenga et al., 2014a). The literature
on psychological outcomes of genetic test disclosure is conflicting. Some studies have evidence
showing that mutation carriers showed an increased level of psychological distress, specifically,
high levels of anxiety and depression, especially in the first months after test disclosure
(Ringwald et al., 2016). In 2012, the American College of Surgeons (ACoS) Commission on
Cancer (CoC) required accredited cancer centers to integrate psychosocial distress screening into
cancer care by the end of 2015 (Ercolano et al., 2018).
Recommendation five of the National Society of Genetic Counselors practice guidelines
notes that the genetics consultation should include extensive client resources, including scientific
information, psychosocial support, and advocacy. Cancer risk assessments can raise several
intellectual and psychosocial issues. High-risk individuals need to contend with an enhanced
understanding of their specific cancer risks, potentially difficult decisions for managing their
cancer risks, concerns about discrimination, and the worry about possible risks and reactions in
their children and other family members (Berliner et al., 2013). Unmanaged psychosocial
distress has a strong potential to impact morbidity and mortality negatively and exacerbate other
comorbid conditions associated with cancer. Optimal distress screening procedures need to be
based on patients’ and families’ self-report of their rating of psychosocial distress and the
problems contributing to the distress (Ercolano et al., 2018).
Current Research Findings
Numerous studies have addressed improved patient outcomes resulting from distress
screening in oncology settings, and cancer genetic risk assessment services help reduce distress,
improve the accuracy of the perceived risk, and increase knowledge about cancer and genetics
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(Garcia et al., 2007; Gentilello et al., 2005; Sivell et al., 2007). The impact of monitoring style on
adjustment seems to be moderated not only by the characteristics of the threat (e.g., degree of
uncertainty in the genetic context) but also by other personal factors (e.g., optimism), contextual
variables (e.g., familial experience with cancer), and interpersonal variables (e.g., monitoring
style of partner). Although more work needs to be done in this area, preparatory or
psychoeducational interventions seem to improve adjustment and adherence to cancer health
threats when the specific demands of the stressful situation are considered (Roussi & Miller,
2014).
Other studies have revealed that cancer risk perception seems to be influenced by
cognitive, social, and cultural factors (Godino et al., 2016; Smith et al., 2008). Alternatively,
other studies have reported that psychological distress, particularly cancer-specific distress, was
significantly associated with refusal or withdrawal from genetic counseling, whether levels of
distress were high or low (Cicero et al., 2017). Genetic results typically are either negative,
positive, or uncertain, and in affected individuals, inconclusive test results are followed by a
range of emotional reactions and misinterpretation of the test results. Individuals who have
inconclusive results are considered a vulnerable group since they request counseling to gain
certainty yet are left in uncertainty instead of the carriers who said they benefited from having an
end to their uncertainty (Schlich-Bakker et al., 2006).
There exists a considerable body of literature on the emotional impact on the BRCA1 and
BRCA2 testing results. Research suggested paying particular attention to a subpopulation
(nonprobands, disease-free individuals) who, contrary to what is usually believed, may be
particularly vulnerable to emotional suffering. Identifying appropriate interventions that target
unmet needs among younger women and those with no confidante may reduce distress (Farrelly
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et al., 2013; Hirschberg et al., 2015; Mella et al., 2017). In a patient-reported outcome study,
Oberguggenberger et al. (2016) noted that certain subgroups of counselees were more vulnerable
to distress, including counselees of older age, with a more recent cancer diagnosis or uncertainty
regarding decisions. The researchers concluded that a detailed exploration of the strongest risk
factors should be integrated into the counseling process and additional psychological support
(Oberguggenberger et al., 2016). Recent studies focused on the psychosocial aspects of the
hereditary cancer screening process as genetic testing is becoming more mainstream, especially
in oncology. However, research regarding the psychosocial implications is new and limited.
Comprehensive distress screening allows for the timely identification, evaluation, and
management of psychosocial distress over the cancer experience. Distress screening tools and
procedures may also result in the discovery of other medical or psychiatric comorbid conditions.
This comprehensive support allows for the care of the “whole patient” (Ercolano et al., 2018, p.
492).
Evidence indicates that the use of psychosocial screening instruments among cancer
patients results in reductions in emotional distress, increased quality of life, and improved
patient-provider communication (Gentilello et al., 2005; Mystakidou et al., 2007; van
Scheppingen et al., 2011; Vodermaier et al., 2009). Lammens et al. (2010) were among the first
researchers to report the uptake and psychological impact of genetic testing for Li-Fraumeni
syndrome (LFS), a hereditary cancer syndrome characterized by a high risk of developing cancer
at various sites and ages. The study noted that a substantial minority of individuals exhibit
clinically relevant distress levels that may warrant formal psychosocial intervention (Lammens et
al., 2010). Several authors have recommended using a screening tool to identify psychosocial
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risk in individuals undergoing hereditary screening (Eijzenga et al., 2014b; Esplen et al., 2013;
Gopie et al., 2012; Lammens et al., 2010).
Previvors have higher levels of psychological distress than BRCA mutation carriers with
breast cancer, nonmutation carriers with breast cancer, and nonmutation carriers without breast
cancer (Dagan & Gil, 2005). If left unmanaged, uncertainty can contribute to poor decisionmaking (Mishel, 1999; Politi & Street, 2011; Wong & Bramwell, 1992) and negative health
outcomes (Arora, 2003). Moreover, women who struggle with risk-related uncertainty are more
distressed and are at risk of long-term distress (O’Neill et al., 2006). Women at risk for breast
cancer face complex risk-related uncertainty for themselves and their families, and while women
may have been initially motivated to do genetic testing to reduce their uncertainty about their
cancer risk (Bylund et al., 2012), receiving positive BRCA genetic testing results still creates
uncertainty coupled with negative emotions that may never dissipate (Dean, 2016; Hoskins &
Greene, 2012; Hoskins et al., 2008; Westin et al., 2011).
Bartley et al. (2020) noted that the complexity of genomic testing introduces new
scientific, practical, and personal uncertainties specific to this process, and the influence of the
type of genomic result and participant uncertainty was mixed. While the quantitative synthesis
showed no difference in uncertainty levels between participants who received positive, negative,
or uncertain genomic results, the qualitative synthesis found decreases in disease and risk
uncertainty for participants who received negative or positive genomic results but increased
uncertainty about the future for participants receiving variance of uncertain significance (VUS)
results. The researchers inferred that while reducing uncertainty can be a motivator for pursuing
genomic testing, results can increase uncertainty.
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A systematic review by Ringwald et al. (2016) investigating the psychological distress,
anxiety, and depression in affected BRCA 1 or 2 mutation carriers noted that understanding the
intermediate and long-term psychological consequences of genetic testing for cancer patients has
led to encouraging research. However, a clear consensus of the psychosocial impact and clinical
routine for cancer-affected BRCA1 and BRCA2 mutation carriers is still missing. The
researchers noted that future studies should implement coping strategies, specific personality
structures, the impact of genetic testing, supportive care needs, and disease management
behaviors to screen for the possible intermediate- and long-term psychological impact of a
positive test disclosure (Ringwald et al., 2016).
The Genetic Psychosocial Risk Instrument
The Genetic Psychosocial Risk Instrument (GPRI) is a validated tool used during
hereditary cancer screenings. When developed and validated, researchers noted that the final 20item GPRI had high reliability and Cronbach was 0.81. A high correlation supported construct
validity. With a cutoff score of 50, the GPRI identified 84% of participants who displayed
distress post genetic testing results, supporting its potential usefulness in a clinical setting
(Esplen et al., 2013). The GPRI was developed to identify individuals liable to experience
significant difficulty adjusting to the genetic information they receive. As such, the GPRI
appears to be a better choice at face value than general anxiety measures for clinicians who wish
to determine whether clients need additional professional support in the wake of genetic testing
(Esplen et al., 2013). The tool was designed to be completed within 10 minutes.
The Supportive Care Screening Questionnaire
The supportive care screening questionnaire was created in 2015 by my clinical
organization’s social workers and APRNs to address the Oncology Care Model (OCM)
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requirement of the IOM care plan. It is a reliable, validated distress assessment tool that
measures the psychometric properties of anger, loss of control, fear, and anxiety in the oncology
setting. The tool was designed to be completed within 10 minutes.
Chapter Summary
Advanced practice registered nurses proved to be equally effective in providing education
about genetic testing compared to genetic counselors (Bernhardt et al., 2000). Public genomic
literacy levels are increasing, in part due to celebrity-driven attention to genetic conditions,
increased use of social media, direct-to-consumer marketing of genetic testing, and the promise
of personalized medicine and targeted therapies for a variety of conditions (King & Smith,
2020). Genetic tests should be proposed along with proper psychological support and counseling
focused on users’ genetic health literacy, perception of risk, beliefs about disease controllability,
and foster fruitful medical decisions (Oliveri et al., 2018). Referral to psychosocial professionals
may be improved by discussing psychopathology during genetic counseling sessions and other
needs and existential concerns (Vos et al., 2013). Consideration of coping strategies, the impact
of genetic testing, or disease management behavior should be implemented in clinical practice to
clear screen for the possible intermediate- and long-term impact of a positive test disclosure
status. Much of what is known about cancer patients’ psychosocial issues related to genetic or
genomic testing is from an overrepresented female and breast cancer perspective. Similarly, most
research investigating patient uncertainty concerning cancer genomic has focused on females
with a personal or family history of breast cancer, highlighting a bias in the literature and a need
for future research to include a more diverse range of cancer patients (Dean & Fisher, 2019).
In patients undergoing cancer risk assessments, there seems to be a certain percentage
within this group that experience heightened anxiety, depression, or distress during or after
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counseling. However, this literature review was conflicting as some studies evidenced that
mutation carriers showed an increased level of psychological distress, categorically, high levels
of anxiety, and depression, while other studies refute that claim. Distress screenings by APRNs
working in oncology in patients undergoing genetic counseling and testing are paramount in
treating the patient holistically as it allows for the timely identification, evaluation, and
management of psychosocial distress during the risk assessment and evaluation period. Evidence
indicated that using psychosocial screening instruments in high-risk individuals resulted in
reduced emotional distress, increased quality of life, and improved patient-provider
communication (Cunningham et al., 2018). Unmanaged psychosocial distress has strong
potential to impact both morbidity and mortality resulting from nonadherence to treatment or
surveillance regimens and poor decision-making, as studies have highlighted adversely.
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Chapter 3: Research Method
This chapter introduces the research methodology used in this quantitative study using
the Genetic Psychosocial Risk Instrument (GPRI) and the Supportive Care Screening
Questionnaire (SCSQ) in identifying high-risk hereditary patients needing psychosocial support
while undergoing genetic counseling and screening. The study utilized an evidence-based
initiative by implementing either the GPRI or SCSQ tools to evaluate whether these tools could
help identify the psychosocial needs in high-risk patients undergoing genetic cancer risk
assessments (GCRA) by APRNs in the outpatient oncology setting. The project’s main goal was
to identify high-risk individuals who needed psychosocial screening and refer them appropriately
by implementing either the GPRI or SCSQ. The applicability of this quantitative approach for
this study is discussed in-depth in this chapter. The research plan, including the methodology,
study participants, procedures, and analysis method, is also a primary component of this chapter.
The research question was: For APRNs in the oncology setting who provide genetic cancer risk
assessments, does the use of the GPRI tool compared to the SCSQ identify psychosocial
concerns and prompt psychosocial referrals in high-risk individuals undergoing hereditary cancer
screening?
Purpose
This evidence-based project’s goals were to (a) identify psychosocial issues while
screening in high-risk individuals, (b) align genetic cancer screening recommendations in highrisk individuals by improving psychosocial management plans, (c) implement and compare two
psychosocial screening tools (GPRI and SCSQ) to determine the appropriate tool to utilize in this
population, and (d) increase shared decision-making referrals based on individual risk factors.
Outcome measures were reflected (a) based on the number of study participants who had
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identifiable psychosocial needs and (b) on the increase in the number of psychosocial referrals in
high-risk individuals undergoing GCRA at a community oncology care clinic in a major city in
Texas. Because this study was designed to examine the use of the GPRI tool or the SCSQ
concerning the number of psychosocial referrals in individuals undergoing genetic screening, a
quantitative approach was the most appropriate choice. The single reality this study assumed was
that those high-risk patients undergoing hereditary cancer screening who needed psychosocial
services had to be identified and referred appropriately during the screening process.
Project Design
This evidence-based project utilized a quantitative comparative design with a
convenience sample. Once high-risk individuals were self-referred or were referred for GCRA,
the clinic schedulers notified me, and I determined if any of these patients met study criteria by
assessing their medical records. If they met the criteria, I would notify the schedulers, who then
made the GCRA appointment and emailed a genetic testing packet. The packet included a patient
welcome letter, family health questionnaire, frequently asked questions (FAQ) sheet, family fact
sheet, force brochure (asking the question, Is the cancer in your family hereditary?), and the
Genetic Information Nondiscrimination Act (GINA) and You information sheet. For this DNP
project, the packet also included a cover letter on the purpose of the research study (see
Appendix A), my name, how the information was going to be used, any potential benefits or
harm the participant could expect, what would happen with the information they shared, and the
informed consent form (see Appendix B). When the high-risk patients came in for their GCRA
visit, I reviewed their consent, asked if they had any questions, and explained the study’s purpose
before signing the consent form. The GPRI (see Appendix C) or SCSQ (see Appendix D) was
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then administered. Based on their GPRI score or SCSQ needs, I referred them appropriately to a
social worker, chaplain, counselor, psychologist, or psychiatrist.
The first unit of analysis included findings from an audit on all study participant charts
and the results of their psychosocial screenings. Demographic data collected included age, race,
gender, education, and a known cancer diagnosis. The second unit of analysis included data from
the GPRI questionnaire. The validated GPRI questionnaire had 20 questions, with 19 of these
questions having assigned scores. If the score was 50 or greater and question 19 was positive, a
psychosocial referral was recommended (Esplen et al., 2013). The third unit of analysis included
data from the SCSQ, which had two parts. Part A addressed the emotional, social, practical
concerns, and Part B addressed depression symptoms. There were two indicators used to
measure the outcomes of the project from the identified participants. The first measure was the
number of referrals generated from the GPRI tool, and the second measure was the number of
psychosocial referrals elicited from the SCSQ tool during GCRA.
Once the institutional review board (IRB) applications were approved by Abilene
Christian University (ACU; see Appendix E), clinic (see Appendix F), and the project chair, Dr.
Aboul-Enein, work began by screening potential study participants from the GCRA referrals. I
assumed responsibility for these project activities, which entailed educating the front desk and
medical assistants and scheduling staff on study objectives, attaining participants’ consents,
executing quantitative measurement scales, and disseminating the results into practice. Key
stakeholders for this project at this community oncology clinic included the four practice medical
oncologists, the region practice manager, the regional nursing manager, I the APRN and the
administrative manager.
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Since the project utilized convenience sampling, every prescreened potential GCRA
referral participant who met study criteria was again informed of the study’s purpose and had all
their questions answered before consent. Once consent was obtained, the GPRI or SCSQ was
administered to the study participants in the privacy of the examining room by me during the
pretesting GCRA phase. Any participant whose score was greater than 50 on the GPRI
questionnaire and any participant who expressed interest in talking with a counselor about their
psychosocial concerns was referred appropriately. On the SCSQ, any participant interested in
getting supportive care was also referred to a social worker, counselor, psychologist, or
psychiatrist.
I collected and compiled data at baseline and utilized a face-to-face interview at the
pretesting phase of the GCRA visit. Three months after study implementation, data obtained
from both tools was reviewed and analyzed to disseminate results. This data included (a) the total
number of patients screened using the GPRI and the total number of patients screened with the
SCSQ, (b) the total number of patients who required additional psychosocial services based on
the screenings with either the GPRI or SCSQ, and (c) the total number of patients who received
psychosocial referrals (see Figure 2). Additional data was also collected, including patient age,
gender, ethnicity, education, and whether the patient was a previvor or had an existing cancer
diagnosis.
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Figure 2
Study Design Schema

Enrollment
Total N = 30: Obtain informed consent. Screen potential
subjects by inclusion and exclusion criteria.

RANDOMIZE

ARM 1
n =15 participants

ARM 2
n = 15 participants

(Pretesting)

Perform baseline
psychosocial assessments
with the GPRI tool, and
refer participants as
prompted.

Perform baseline
psychosocial assessment
with the SCSQ tool, and
refer participants as
prompted.

(Month 3)

Final assessment on study
endpoints and evaluation of
psychosocial referrals.

Final assessment on study
endpoints and evaluation
of psychosocial referrals.

Methodology Appropriateness
This evidence-based project measured the key indicator: the number of referrals
generated from either the GPRI or the SCSQ tools. A systematic probability convenience
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sampling, which was randomized, was utilized in this study. The project design had two arms.
Study participants in arm one had their psychosocial status assessed utilizing the GPRI tool, and
those in arm two were assessed with the SCSQ tool. To meet the study objectives, data from this
project was quantified based on the interpretive research approach, a quantitative research
method best suited for this project. Confounding variables included the subject’s negative
perception of the referral process if psychosocial issues were identified. Data collection in this
evidence-based project was collected via a nonprobability sampling because of feasibility issues
related to time.
Feasibility and Appropriateness
I currently practice in an outpatient oncology clinic in a major city in Texas. The clinical
site participates in the Genetic Risk Evaluation and Testing (GREAT) program, which provides
in-depth cancer risk evaluations by trained APRNs. In the current clinical setting, psychosocial
concerns are not addressed in high-risk individuals undergoing genetic testing. Participants were
self-referred or provider referred for genetic counseling services under the GREAT program. The
GREAT program was implemented in January 2019 at the investigator’s outpatient oncology
clinic, which sees an average of 15 new high-risk hereditary patients each month. Since program
implementation, I have seen 154 high-risk hereditary cancer patients and has established a highrisk cancer clinic. Outcome achievability was obtainable through the applications of a statistical
approach that validated the use of quantitative measurements. There were no associated financial
costs obligated to the organization for the support of this project.
IRB Approval and Process
The IRB board of ACU and the IRB board at my clinical site granted permission to
conduct this DNP project titled “Assessing Psychosocial State in High-Risk Individuals
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Undergoing Genetic Screening.” Dr. Faisal Aboul-Enein (chairperson) supervised me. ACU’s
training process included the National Institutes of Health (NIH) Protecting of Human Subjects
and Research Participants Training and Ethics completed within the preceding months before
initiating the project. The date of completion was September 8, 2020 (see Appendix G). The
good clinical practice and human subjects training was required by my clinic and completed on
November 21, 2019 (see Appendix H). A comprehensive introduction to ethics and human
subject protection course offered by the association of clinical research professionals (ACRP)
was completed on February 4, 2021 (see Appendix I) as part of my clinic’s IRB approval
requirement. Data from all participants was anonymized, and no participants were identified by
name or any other manner during or after the study.
Interprofessional Collaboration
Consultation with scholarly authors was obtained during this project with permission
from Dr. Mary Jane Esplen, whose GPRI tool was utilized, and Dr. [redacted] (see Appendix J),
registered nurses who helped develop the SCSQ for my clinical practice. Collaboration with
psychologists and counselors at the San Antonio Counseling and Behavioral Center (SACB),
licensed social worker Rebecca Clinton MSW, LCSW, and psychiatrist Dr. Mark Drogin.
Collaboration with this interdisciplinary team was crucial in coordinating and developing this
project.
Practice Setting
This project’s study and implementation were completed at a community clinic in Texas.
The clinic is an outpatient cancer center with four medical oncologists and two APRNs. The
clinic offers a robust array of leading-edge treatment options in cancer care, including
chemotherapy and immunotherapy treatments. The APRNs perform all treatment review and
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coordination (TRC), advance care planning (ACP), survivorship visits, and genetic cancer risk
assessments (GCRA). The clinic is part of a larger physician-led network and has 210 locations
throughout Texas and Southeastern Oklahoma, with 500 physicians across Texas and 162 midlevel providers. One hundred four of the mid-level providers participate in the GREAT program.
The regional practice director granted permission to utilize this clinic for the proposed project
(see Appendix K).
Target Population
The target population included high-risk individuals diagnosed with cancer, primarily
breast, ovarian, colorectal, pancreatic, gastric, prostate, and melanoma cancers. The participants
included previvors who had family histories of these cancers in either first-degree or seconddegree relatives, patients and their previvors diagnosed with cancer before the age of 50, and
patients who had family members with first-degree relatives with known cancer mutations. Highrisk individuals also included previvors with multiple individuals in a family who had the same
cancer, patients or those who have had cancer develop in paired organs (both breasts, both
ovaries, both kidneys), and patients who have had multiple cancers occur in the same individual.
Subject diversity was preferred. Patient participants were limited to those who were English
speaking only. Exclusion criteria included current oncology patients who did not have primarily
breast, ovarian, endometrial, colorectal, pancreatic, gastric, prostate, and melanoma cancers,
patients with mental disorders, and patients referred for post GCRA visits without pretesting by a
trained genetics APRN.
Risks and Benefits
There were minimal anticipated risks associated with this study’s implementation, from
consent procedures, data collection, data measurements, evidence dissemination, and translations
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into practice. There were no preconceived benefits, including no monetary compensation or
rewards for participating in the study. Research participants remained anonymous and only
identifiable with a unique identification number given at the study initiation. All ethical
principles were maintained. There were no identified conflicts of interest in this study. This
study’s limitations included unforeseen time constraints, small population size, patient mortality,
and individuals who had been referred for post counseling results without pretest. The sample
population was a convenience sample, potentially weakening the internal and external validity of
the study. The sample population was small, potentially affecting the significance of the findings.
Instruments and Measurement Tools
Demographic data for study participants included age, ethnicity, gender, education, and
cancer diagnosis. I administered to each study arm the GPRI and the SCSQ at the end of the
GCRA visit. The demographic data, GPRI score, SCSQ information, and data of kind of referral
placed were then inserted in a data analysis tool in Microsoft Excel. After the three-month study
period, a review on the number of psychosocial referrals elicited by each tool was made. I chose
this measurement tool because it is a nonintrusive strategy for collecting data and speed of
review. The tool is also practical, inexpensive, and effective.
Data Collection
During the project timeline and implementation (see Table 1), personal identifiers,
including gender, ethnicity, age, race, type of cancer, and cancer treatment type, were
documented. There was no preintervention data on the psychosocial referrals as psychosocial
assessments were not currently conducted for high-risk individuals undergoing GCRA with the
APRNs. The GPRI has 20 questions, the SCSQ has two parts, and I administered either
questionnaire during the pretesting GCRA visit. Appropriate referrals were ordered in the
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IKnowMed G2 system based on elicited answers, and data was accessible in real-time.
Postintervention data points included the total number of high-risk individuals seen by the
investigator for three months, the total number of GPRI and SCSQ administered, the total
number of positive psychosocial screenings, and the total number of referrals elicited by each
tool for a total of three months of data collection.
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Table 1
Project Timeline
Scholarly project milestone(s) completed

Month/year
completed

Letter of support received from the Practice Site

05/2020

PICO developed and completed

06/2020

Theoretical framework paper completed

06/2020

Chair/committee members secured for the project

06/2020

Mini proposal approved

07/2020

EBP tool (GPRI) permission email received from the author

08/2020

Chapters 1–3 revisions completed, reviewed by chair and committee members

10/2020

Proposal defense

11/2020

IRB proposal for Abilene Christian University

01/2021

IRB proposal for clincal site

02/2021

Secured IRB proposal

02/2021

Project implementation (three months)

03/2021

Project analysis for Chapters 4–5

07/2021

Chapters 4–5 revisions completed, reviewed by chair and committee members

09/2021

Final project defense

09/2021

Participants’ privacy was protected, and any identifying information was redacted from
the recordings. The identified data collected during this project was stored in a secure university
password-protected drive under the researcher’s name. The university will own data in case
access is needed at a future date. This storage system was provided by the online graduate school
for doctoral student research data and supported by the university’s information technology (IT)
department for security purposes and kept for the minimum required time according to IRB
guidelines. Outcomes were measured by determining the number of referrals to other health care
providers as needed, including social workers, psychiatrists, psychologists, or counselors.
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Analysis Plan
The Statistical Package for the Social Sciences (SPSS) was used to perform a descriptive
analysis of the data, and the Pearson chi-square was chosen to determine whether there were any
variances between the two groups being compared (high-risk patients subjected to the GPRI
screening tool versus high-risk patients subjected to the SCSQ tool). Data was transferred
directly from an Excel spreadsheet into the SPSS software. The null and the alternative
hypothesis were:
H0: There will be no difference in the number of referrals made to social workers,
psychiatrists, psychologists, or chaplains in high-risk individuals subjected to the GPRI versus
those subjected to the SCSQ tools.
H1: The GPRI screening tool will identify more psychosocial concerns compared to the
SCSQ in high-risk individuals undergoing hereditary cancer screening, which will prompt more
referrals to social workers, psychiatrists, psychologists, or chaplains.
The Pearson chi-square test was utilized with an alpha of 0.005, as I determined whether
there is an association between the choice of the screening tool and the number of referrals
generated using a bivariate table. Cross-tabulation presented the distributions of the GPRI and
SCSQ with three variable intersections of “accepted referral, declined referral, or did not need a
referral.” Recording of study data was recorded on an Excel spreadsheet with both variables
identified by the investigator. A nonprobability sample was chosen because of feasibility issues
related to time and costs to obtain a random sample at this oncology clinic. The sample size
depended on the availability of newly referred and current patients, but the aim was about 15
participants total in both groups. The G*Power to conduct a priori power analysis to calculate
sample size was computed. For a power of 0.80 with an alpha of 0.005 and a moderate effect
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size, it was determined that a sample of 30 patients was needed. An additional 10% was added to
account for attrition for patients who declined participation, bringing the total sample required to
30 patients. A unique participant identification number was allocated at baseline.
Chapter Summary
The role of the DNP defined by Essential II of the Essentials of Doctoral Education for
Advanced Nursing Practice requires proficiency “in quality improvement strategies and in
creating and sustaining changes at the organizational and policy levels” (American Association
of Colleges of Nursing, 2006, p. 10). This study tried to ascertain whether the GPRI tool in highrisk individuals undergoing hereditary cancer screening would help identify those patients
needing psychosocial services. The study participants had been referred to undergo genetic
counseling and testing services at an outpatient community cancer center in a major city in
Texas. Inclusion and exclusion criteria were applied, and the quantitative analysis project design
supported the study methodology. No time constraints were identified with the project
development, and all requirements were met before IRB approval. The estimated timeline for
completion was three months.
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Chapter 4: Findings
This chapter presents the results of the data analysis, including the quantitative survey
results. This evidence-based project utilized a quantitative comparative design. It evaluated the
efficacy of the Genetic Psychosocial Risk Instrument (GPRI) and the Supportive Care Screening
Questionnaire (SCSQ) in identifying the psychosocial needs of high-risk individuals undergoing
genetic cancer risk assessments (GCRA) by advanced practice registered nurses (APRNs) in the
community oncology setting. This research design was more desirable as I ) tried to ascertain a
linear relationship between the two quantitative variables (GPRI or SCSQ) in psychosocial risk
identification. The research study fulfilled the two assumptions required to analyze data with the
Pearson chi-square test in that both questionnaires (independent variables) and the number of
psychosocial referrals (dependent variable) were measured at a nominal level. Secondly, both the
independent and dependent variables had two or more independent groups. The independent
variable groups that met this criterion were the use of the GPRI or the SCSQ tools, and the
dependent group that met this criterion was the number of study participants who either
accepted, declined, or did not need a psychosocial referral.
The study utilized a systematic convenience sample of 30 participants randomized in two
arms to receive either the GPRI or SCSQ. The number of psychosocial referrals elicited by the
GPRI or SCSQ was tabulated at the end of the three-month study period. The demographics are
described, and key findings are highlighted. The project data was collected from March 12, 2021,
to June 24, 2021. Forty-two participants were screened, and 33 potential study participants met
the study criteria, with three declining participation.
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Purpose of the Project
This DNP quality improvement project’s overall aim was to improve psychosocial
screening practices, implement and compare two psychosocial screening tools to help identify
psychosocial concerns, and increase psychosocial referrals in high-risk individuals undergoing
genetic testing at a community outpatient oncology clinic in Texas.
The goals of this study were:
a. to identify psychosocial risk factors in individuals with heightened cancer risk;
b. to improve psychosocial management plans and increase shared decision-making
referrals based on individual risk factors; and
c. to determine the appropriate psychosocial risk tool to utilize in the community oncology
setting.
Administering either the GPRI or SCSQ psychosocial risk assessment tools at the initial
GCRA visit by the APRN helped identify study participants who needed additional psychosocial
support. These patients were then referred to a social worker, counselor, psychologist, or APRN
for advanced care planning or psychiatrist based on their scores on the GPRI or answers on the
SCSQ. The psychosocial concerns noted on the SCSQ were fear, worry, anxiety, sadness, feeling
like a burden to others, support for children and teens, support for the caregiver, insurance,
needed help with advanced care planning (ACP), and guidance with social security. On the other
hand, the psychosocial concerns that the GPRI tool identified in this study included guilt,
sadness, nervousness, anxiety, relationship worries about potential genetic results, worries about
children, worries about professional careers, daily mood, guilt about passing on disease risk to
children, and problems in life arising from genetic results. Study outcomes were observed after
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administering the two questionnaires and included the results from the total number of study
participants who needed psychosocial referrals in both the GPRI and SCSQ groups.
Demographics
From March 2021 through July 2021, 42 participants referred for genetic counseling were
screened, and 30 of them met the criteria for study participation. The participants’ ages ranged
between 22 and 78 that were referred for GCRA with me.. The median age of the participants
was 47. The sample size included 30 patients, of which 16.7% were male, and 83.3% were
female. The participants were 10% African American, 53.3% Caucasian, and 36.7% Hispanic.
With respect to scholarship, 16.7% of the study participants had a high school diploma, 13.3%
had a certificate, 10% had an associate’s degree, 36.7% had a bachelor’s degree, and 23.3% had
a master’s degree. Previvors comprised 56.7% of the study participants, and 43.3% had a cancer
diagnosis. Of the 43.3% who had a cancer diagnosis, 15.3% had colon cancer, 23% had rectal
cancer, 7.6% had testicular cancer, 23% had breast cancer, and 7.6% had a history of Hodgkin’s
lymphoma. Twenty-three percent of the study participants comprised one male and two females
who had more than one cancer diagnosis. The first female had breast and pancreatic cancer, the
second female had breast, uterine, and pancreatic cancers, and the male participant had prostate
and pancreatic cancers.
The targeted facility was an outpatient oncology clinic in a major city in Texas and the
project was conducted during regular clinic hours, Monday through Friday. The reason for
choosing this site was that the study group consisted of high-risk individuals who were either
self-referred or referred by other health care providers based on their type of cancer or family
history. The project implementer was her own support service, explaining and obtaining the
informed consent, administering the questionnaire, and analyzing the data.
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Data Analysis
I utilized the SPSS version 20.0 software program for statistical analysis and obtained
frequencies, percentages, mean and standard deviation (SD) to describe the sociodemographic
and clinical characteristics. A dichotomous variable was generated for the GPRI and the SCSQ
screening tools, grouping “accepted referral, declined referral, or no referral needed” categories.
The Pearson chi-square analysis was employed to determine and compare any relationship
between the variables of the two instruments simultaneously. The Pearson chi-square was used in
this study because (a) the independent variable (questionnaire) and dependent variable
(psychosocial referrals) were measured using a nominal scale, and (b) both the independent and
dependent variables had two more categorical independent groups. In this study, the independent
variable, which was the use of the questionnaire, contained either the GPRI or SCSQ group. The
dependent variable was the psychosocial referrals that had grouped variables as “accepted
referral,” “declined referral,” or “no referrals needed.” Since fewer than five expected cases were
in the 2x2 cells, Fisher’s exact test was used (Plichta & Kelvin, 2015).
Questionnaire comparison revealed that the GPRI detected 10 patients with psychosocial
needs, four of whom declined psychosocial referral compared to 11 identified patients in the
SCSQ arm, five of whom declined psychosocial referrals. However, an equal number of patients,
40% in both the GPRI and SCSQ arms, accepted psychosocial referrals to social workers,
counselors, and psychiatrists. One-third of those in the SCSQ arm declined referrals even when
clinically appropriate compared to 26.7% in the GPRI arm. One-third in the GPRI arm did not
need referrals compared to 26.7% in the SCSQ arm. Pearson chi-square analysis revealed χ (1) =
1.222, p = .895, so there was no statistically significant association between referrals and
assessment tools.
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Table 2 represents the association between the use of the GPRI or SCSQ and the referral
the tools elicited. The number of psychosocial referrals increased from 0%–40% during this
project implementation phase in high-risk individuals subjected to the GPRI versus those
subjected to the SCSQ tools. Counselors and social workers received the most referrals out of all
specialty resources personnel.
Table 2
Referral and Questionnaire Cross-Tabulation
Questionnaire
Referral type

Count

Accepted Referral

Count
Expected Count
% within Questionnaire

Declined Referral

Count
Expected Count
% within Questionnaire

No Referral

Count
Expected Count
% within Questionnaire

Total

Count
Expected Count
% within Questionnaire

GPRI

Total
SCSQ

6

6

12

6.0

6.0

12.0

40.0

40.0

40.0

4

5

9

4.5

4.5

9.0

26.7

33.3

30.0

5

4

9

4.5

4.5

9.0

33.3

26.7

30.0

15

15

30

15.0

15.0

30.0

100.0

100.0

100.0

Table 3 represented the descriptive analysis with the Pearson chi-square analysis, which
revealed χ (1) = 1.222, p = .895. There was no statistically significant association between
referrals and assessment tools. The null hypothesis was accepted as the p-value (.895) and was
greater than the alpha (.005). The null hypothesis noted that there would be no difference in the
number of referrals made to social workers, psychiatrists, psychologists, or chaplains.
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Table 3
Descriptive Statistics: Chi-Square Tests

Variable
Pearson Chi-Square

Value
.222a

df
2

Asymptotic
Significance
(2-sided)
.895

Likelihood Ratio

.223

2

.895

Linear-by-Linear Association

.047

1

.829

N of Valid Cases

30

Note. a. Four cells (66.7%) have expected count less than 5. The minimum expected count is
4.50.
Reliability and Validity
I personally applied the two instruments utilized in this project during the first
appointment. The time required to complete the evaluation was 10 minutes for each instrument.
With a cut-off score of 50, the 20-item GPRI has good reliability and validity as it identified
66.6% of study participants who had psychosocial risk factors who needed psychosocial
referrals. These findings supported the GPRI’s potential usefulness in the outpatient clinical
setting. The SCSQ two-part questionnaire with 22 items based on six factors also had good
reliability and validity. It identified 73.3% of study participants who had psychosocial risks and
needed psychosocial referrals.
Chapter Summary
The current scope of nursing practice stipulates genetic and genomic literacy. In the
advent of APRN-run high-risk hereditary cancer clinics, APRNs play a crucial role in evaluating
individuals who have an increased risk of developing cancer, providing comprehensive health
education, and importantly individualizing recommendations based on risk. This study’s findings
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revealed that in high-risk individuals undergoing GCRA, 70% needed additional psychosocial
support beyond a medical assessment. Advanced practice registered nurses play a crucial role in
screening and addressing the psychosocial issues associated with GCRA and must evaluate these
needs and make appropriate referrals as needed. According to Pasacreta (2003) and Voorwinden
and Jaspers (2016), approximately 10%–25% of counselees experienced heightened levels of
distress during and after the genetic counseling process, but genetic counselors often failed to
recognize and address these issues since they tend to be more focused on gathering and giving
medical information (Meiser et al., 2008). They also lacked the appropriate tools to assess the
specific psychosocial problems and distress levels experienced by counselees.
Among the adverse psychological responses identified in this study, the most frequent
included worry about the possibility of having a genetic mutation, worry about passing the genes
to their children, stress about personal relationships, sadness, fear, guilt, depression, anxiety, and
uncertainty. Forty percent of patients accepted their psychosocial referrals to counselors,
psychologists, and psychiatrists, indicating a need to correctly identify these patients and refer
them appropriately in the community oncology setting. Secondly, engaging patients in decisionmaking, particularly on their psychosocial concerns as it relates to the GCRA process, is
essential as it helps these patients have possible psychosocial benefits such as relief from
uncertainty, a satisfaction of curiosity, relief of guilt, improved family supports, and optimistic
empowerment (Wade, 2019). It is well understood that effectively engaging patients in their care
is essential to improve health outcomes, improve satisfaction with the care experience, reduce
costs, and even benefit the clinician experience (Krist et al., 2017). Both the SCSQ and GPRI
questionnaires effectively identified the psychosocial needs in this high-risk patient population.
Chapter 5 includes a discussion of the interpretations, inferences, and implications of the study
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findings. Recommendations for APRNs who provide high-risk hereditary cancer screening
services and recommendations for future research will also be addressed.
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Chapter 5: Discussion of Findings
The purpose of this project was to evaluate psychosocial risks in high-risk hereditary
cancer patients undergoing genetic cancer risk assessments (GCRA) by oncology APRNs in the
outpatient community setting. Genetic screening for inherited cancer risk is an uncomplicated
test in its execution, but it holds compelling information for individuals and their families
regarding health and illness across the lifespan. Indeed, the psychosocial issues that arise from
genetic testing interact with elements of individual personalities and cognitive capacity affecting
relationships with others, striking at the core of an individual’s identity (Wasserman, n.d.). The
Genetic Psychosocial Risk Instrument (GPRI) and the Supportive Care Screening Questionnaire
(SCSQ) were utilized as psychosocial assessment tools in this study. This chapter discusses the
interpretation and inference of the findings and implications of the analysis for leaders relevant
to the study results. Recommendations are presented for APRNs who provide high-risk
hereditary cancer screening services and recommendations for future research.
This project determined that in high-risk individuals undergoing GCRA, 70% had
identifiable psychosocial needs, and 43% of these patients were willing to get additional
psychosocial support to address these needs. It has been reported that low social support and a
personal or familial history of cancer are risk factors for anxiety (Eijzenga et al., 2014a). This is
important because anxiety levels have been associated with decision-making, compliance to
screening methods, and risk-reduction measures (Hart et al., 2012). As a result, oncology APRNs
who perform GCRA must identify the psychosocial needs of all individuals participating in highrisk hereditary cancer screening, including making appropriate support referrals when identified.
The literature review revealed that individuals undergoing GCRA had been shown to benefit
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from additional psychosocial support as it helps reduce treatment nonadherence or surveillance
regimens and improved decision-making.
Currently, there are only two validated psychosocial screening tools specific for
hereditary cancer screening: the Genetic Psychosocial Risk Instrument (GPRI) and Psychosocial
Aspects of Hereditary Cancer (PAHC) questionnaire. To measure study outcomes, the SCSQ
was selected for this study because it is a supportive screening questionnaire that pulls reference
from the validated Edmonton Symptom Assessment Scale (ESAS) and validated Patient Health
Questionnaire-2 (PHQ2). Also, the SCSQ is currently being utilized at the clinical site and
systemwide at [redacted] to assess psychosocial needs in patients undergoing cancer treatment
only. It is not utilized in GCRA visits. The second instrument, GPRI, was chosen because it is a
validated tool and the first reported psychosocial screening instrument used for adult-onset
hereditary disease (Esplen et al., 2013). Another validated tool for use in this study was the
Psychosocial Aspects of Hereditary Cancer (PAHC) questionnaire developed by Eijzenga et al.
(2014b). This questionnaire was considered but not chosen because the authors had
recommended that it be used in combination with the distress thermometer. Most of the
psychosocial screening tools like the Patient Health Questionnaire-9 (PDQ9), Hamilton
Depression (HAM-D) rating scale, and Hamilton Anxiety (HAM-A) scale were not specific to
GCRA and were not oncology or high-risk cancer screening specific.
Interpretation and Inference of Findings
This project showed that a certain percentage of patients undergoing hereditary cancer
risk assessments experienced heightened anxiety, depression, guilt, worry about the risk of
disease and passing down genes to their children, fear about illness if positive, relationship
worries, or distress during or after genetic counseling. This is important because it has been
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demonstrated that the application of either the SCSQ or the GPRI questionnaires provides greater
understanding and sensitivity to identify psychosocial alterations in high-risk individuals
undergoing hereditary cancer screening. It has been reported that low social support and a
personal or familial history of cancer are risk factors for anxiety (Eijzenga et al., 2014a). Anxiety
levels have been associated with decision-making, compliance to screening methods, and riskreduction measures (Hart et al., 2012). The high-risk hereditary cancer population has been
shown to benefit significantly from additional psychosocial support referrals as needed during
this process. Therefore, oncology APRNs who perform hereditary cancer risk assessments must
identify the psychosocial needs of all individuals participating in high-risk hereditary cancer
screening, including making appropriate support referrals when identified.
There was a correlation between the variables evaluated by the GPRI and SCSQ, and
study results suggest that cancer-related worries, guilt, anxiety, and depressive symptomatology
affect the well-being of these high-risk individuals. These results suggest that either tool can be
applied to identify participants who would require psychosocial support during the hereditary
cancer screening process by APRNs in the outpatient community oncology setting. Since there is
no “gold standard” in the choice of psychosocial screening tools, the tools utilized will typically
be APRN-subjective as this study proves that both screening questionnaires were adequate in
prompting psychosocial referrals as needed. However, the SCSQ identified more patients who
needed referrals and will be implemented in all the 210 clinical sites with APRNs providing
high-risk GCRA services. The clinical site’s psychosocial referrals went from 0% to 70% during
the study implementation phase, which is relevant as it highlights an identifiable gap in care that
needs to be continually addressed. The use of psychosocial screening tools resulted in detecting
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other medical or psychiatric comorbid conditions, which prompted psychosocial referrals to the
appropriate clinicians and, most importantly, improved patient-provider communication.
The significant findings and points that relate to the overall purpose of this project
included identifying psychosocial concerns in high-risk hereditary cancer patients who came in
for their GCRA visits with the APRN. Forty-three percent of these patients accepted their
psychosocial referrals. These study findings assist the APRN in providing a comprehensive
cancer risk assessment as stipulated by the NCCN guidelines, which advocates for the need for
patients and families to be informed that distress management is an integral part of total medical
care and that they are provided appropriate information on the psychosocial services. One of the
goals of this study was to implement a psychosocial screening tool that can be utilized in clinical
practice by APRNs conducting genetic counseling visits following the standards of care (SOC)
stipulated by NCCN. Two of the NCCN’s SOC prescribe that the quality of distress management
programs or services should be included in institutional continuous quality improvement (CQI)
projects and that interdisciplinary institutional committees should be formed to implement
standards for distress management (NCCN, 2020).
The study’s findings revealed that in a certain percentage of patients, and this case, that
70% of the patients had identifiable psychosocial risk factors, and 43% of those patients accepted
psychosocial referrals to counselors, APRNs, social workers, counselors, psychologists, and
psychiatrists. Studies investigating distress screening, referral, and acceptance of professional
support services found low correspondence between emotional distress and uptake. Some studies
found that patients who reported a higher burden of emotional symptoms were more likely to
access services than those who reported a lower burden of symptoms (Zwahlen et al., 2017).
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The reasons provided by patients about not wanting to see a psychosocial
interdisciplinary team member were time constraints, not sure if insurance would cover
counseling services, and wanting to wait on their genetic results before considering a
psychosocial assessment by another health provider. Most of the patients felt that they could selfmanage symptoms and that they did not feel distressed enough. They also felt that they did
receive adequate support from friends and family. There was an increase in shared decisionmaking between me and the study participants, and more importantly collaboration with other
disciplines. Understanding these new findings presented in this project helps add to the current
nursing body of knowledge about high-risk individuals undergoing GCRA by APRNs, including
assessing these individuals’ psychosocial needs, addressing these needs, and tailoring
individualized treatment plans. These treatment plans help address these patients’ uncertainties,
improve psychosocial function, and allocate valuable psychosocial resources that promote
surveillance and treatment adherence. Early identification of these high-risk individuals at a
potentially higher risk of suffering distress and adverse psychological effects during GCRA
enhances preventative health delivery, which helps improve decision-making, preserves
adherence to treatment and surveillance regimens, and impacts cancer morbidity and mortality
rates.
Recently, there has been increasing debate over the lack of appropriate measures for
psychosocial impact in genetic or genomic medicine, with some authors highlighting a need to
use cancer-specific scales. However, there is currently limited research assessing the long-term
psychological outcomes of genomic cancer testing (Yanes et al., 2019). Oncology APRNs who
have been trained in GCRA must identify any psychosocial needs in high-risk individuals and
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during the hereditary screening process and facilitate psychosocial resources that can help these
individuals cope with their psychosocial concerns and needs.
Limitations
Limitations associated with the project included issues related to self-reporting because
the study participants filled out the assessment tools. In addition, a small sample size was used
due to the three-month study time frame and dependence on incoming and clinical referrals,
affecting the statistical significance level. A larger sample size would have provided greater
power in detecting any difference between the two psychosocial risk assessment tools.
Implications for Leaders
Genomic testing is expeditiously being integrated into clinical settings to direct
population screening programs and testing of tumor cells to guide cancer treatment. At the
clinical site, there was demonstrated need for standardized identification of psychosocial support.
It is essential that oncology APRNs advocate, initiate psychosocial screening measures, and
ensure the delivery of high-quality care by ensuring these high-risk individuals receive the care
and support they need during the high-risk hereditary screening process. Advanced practice
registered nurses in the oncology setting are ideal health care providers to assess patients’
psychosocial needs, provide guidance, and make psychosocial referrals and recommendations.
Targeting screening to high-risk populations is likely to have significant benefits in health care
by making allocated resources more efficient and reducing the burden of routine care for those at
the lowest risk (Yanes et al., 2019). As noted with this study findings, a significant amount of
high-risk hereditary cancer patients reported higher levels of anxiety, depression, worry, negative
mood, and genetic risk perception, thus being at risk for psychological discomfort during the
counseling process. Therefore, resources and programs should be put in place to accommodate
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psychosocial referrals within the interdisciplinary context in inpatient, outpatient, and
community settings.
With a growing need for oncology nurses to integrate genetic and genomic information in
every aspect of oncology nursing care, this research has generated new information for oncology
APRNs by providing a frame of reference on how some high-risk individuals undergoing
hereditary cancer screening and testing need their psychosocial needs assessed. This is important
because oncology APRNs play an evaluative role in identifying psychosocial risk factors in this
patient population that can impact mental health, adherence to surveillance, or treatment plans as
recommended. Improving cognizance among oncology APRNs working in the outpatient
community setting and encouraging the development or expansion of an interdisciplinary
network comprising social workers, counselors, chaplains, psychologists, and psychiatrists can
help improve continuity of care and provide comprehensive cancer care to these high-risk
individuals. The results from this DNP project conclusively indicated that high-risk individuals
undergoing GCRA identified the need for additional psychosocial support. Positive results were
produced from this project as evidence revealed that both psychosocial risk assessment tools
utilized could identify psychosocial needs prompting psychosocial referrals.
In congruence with the Institute of Health (IHI) Triple Aim Initiative, nurse leaders and
especially DNP-prepared nurses are called to improve the patient experience of care. This project
highlights the need for utilizing a psychosocial screening tool to help identify psychosocial needs
in high-risk individuals undergoing GCRA and refer them appropriately, which helps improve
health quality and patient satisfaction. Secondly, the GCRA process by oncology APRNs helps
identify individuals at risk for developing cancer and helps minimize these risks by promoting
early-detection education and strategies to help lower this risk. This notion aligns with the
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second triple aim initiative of improving population health as genetic or genomic literacy is
available to individuals, communities, and diverse populations. The third triple aim initiative
calls for reducing the cost of health care, and the early detection of elevated cancer risk and early
detection of psychosocial risk in high-risk individuals helps reduce the cost of health care. In
cancer patients undergoing GCRA, this testing allows the sparing of unnecessary use of costly
procedures or treatments as the presence of specific genomic markers paves the way for targeted,
individualized therapy, saving health care dollars. Also, in previvors, the presence of a genetic
mutation that can lead to cancer, a very costly disease, can be reduced by prophylactic surgeries
or increased diagnostic screening, which reduces the individual’s financial cost and saves their
lives. A systematic review conducted by Jansen et al. (2016) on cost-effectiveness and costutility of psychosocial care in oncology noted that psychosocial care is likely to be cost-effective
at different, potentially acceptable, willingness-to-pay thresholds.
Outcomes from this DNP project indicated that oncology APRNs and especially those
trained in providing GCRA services should work with other health care providers to provide
comprehensive, individualized cancer genetic and genomic care, including assessing
psychosocial risk. The results produced several implications for nursing practice according to the
eight DNP Essentials and the Essentials of the Doctoral Education for Advanced Nursing
Education Practice (American Association of Colleges of Nursing, 2006) for APRNs, which will
be discussed further.
Essentials of Doctoral Education for Advanced Practice Nurses
Essential 1: Scientific Underpinnings for Practice
Psychosocial distress in high-risk individuals undergoing hereditary cancer screening is
evident in some of these individuals who report worry, guilt, anxiety, depression, fear, and risk-
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related uncertainty. The literature review helped support the benefits of identifying and
addressing psychosocial concerns in these individuals. The literature review and this study
findings could provide a basis for generalizing and assimilating this intervention in the outpatient
oncology setting and wherever high-risk individuals present for hereditary cancer screening.
With the recent advent of APRN-run high-risk cancer clinics and more APRNs getting training
in providing genomic counseling and testing, measures should be put in place to treat these highrisk individuals comprehensively or by focusing on an individual as a whole. The DNP allows
for the homogenization of nursing science from knowledge derived from psychosocial science in
this project, which also reinforces nursing science concepts.
The theoretical framework guiding this research project was the reconceptualized
uncertainty in illness theory (RUIT) by Mishel (1990). The theory reinforces that in the GCRA
process, uncertainty and risk management is an ongoing, distressful chronic experience, which is
characterized by emotional and psychological distress and inevitably tied to an individual’s
ongoing risk-related uncertainty (Dean & Fisher, 2019). Research informed by RUIT suggests
that patients appraising uncertainty as a danger will experience negative emotions and poor
health outcomes (Clayton et al., 2018; Kang, 2006). Any uncertainty must be assessed
throughout the hereditary cancer screening process by oncology APRNs providing this service.
Some nursing interventions informed by RUIT that can help high-risk individuals undergoing
hereditary cancer screening are using an appropriate psychosocial screening tool that addresses
emotional concerns and assessing and referring these individuals appropriately to help them
explore the emotional and social conditions from which meaning of the disclosed event is
attained. Reconceptualized uncertainty in illness theory can be applied in any clinical setting
where GCRA services are being provided. It serves as a suitable framework to disseminate
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information that helps advance foundational nursing interventions for practice change and health
promotion, which helps develop the DNP provider as a nursing scientist.
Essential 2: Organizational and Systems Leadership for Quality Improvement and Systems
Thinking
There is an identifiable need to evaluate psychosocial status in high-risk individuals
undergoing hereditary cancer screening as most of these individuals endorse having psychosocial
concerns associated with the hereditary screening process. Since genetics is a recognized nursing
specialty and genetic testing services are now being offered by trained APRNs as a contemporary
nursing science, the development of new care delivery models to meet the needs of this patient
population based on this study’s findings can help promote the quality of care and excellence in
practice. Systemic organization arrangements should be put in place to ensure that psychosocial
screening services are incorporated during the GCRA process and must include an
interdisciplinary network of counselors, social workers, chaplains, psychologists, and
psychiatrists for patients who have been identified as needing psychosocial services. Practice
policies that affect clinical flow during the hereditary screening process should be updated to
include psychosocial screening at each pre GCRA visit by the APRN. Integrating an electronic
psychosocial referral system into the interdisciplinary team is vital to the success of this practice
change.
Essential 3: Clinical Scholarship and Analytical Methods for Evidence-Based Practice
Assessing the need for psychosocial screening in high-risk individuals undergoing
hereditary cancer screening by oncology APRNs in the research practice revealed that some of
these individuals had psychosocial needs that required an interdisciplinary team approach to
manage clinical outcomes. As it is known, risks associated with genetic testing include emotional

55
distress, psychological harm, and potential insurance and employment discrimination (Smith et
al., 2004). Integration across disciplines, including social work, psychology, hospitality, and
psychiatry, has been shown to address these psychosocial issues related to the hereditary
screening process. Genetic tests should be proposed along with proper psychological support and
counseling focused on users’ genetic health literacy, perception of risk, and beliefs about disease
controllability to foster fruitful medical decisions (Oliveri et al., 2018).
The two survey instruments utilized in this project included the Genetic Psychosocial
Risk Instrument (GPRI) and the Supportive Care Screening Questionnaire (SCSQ). The SCSQ
identified more patients in this project with psychosocial issues and was an easy, expeditious,
and effective tool to assess and address the high-risk individuals’ feelings and concerns about the
GCRA and genetic results. The APRN can implement this survey at the pregenetic counseling
phase of GCRA and prompt psychosocial referrals if warranted. As a practice that is part one of
the nation’s largest networks of integrated, community-based oncology practices and with 118
APRNs trained in genetics through the Genetic Risk Evaluation and Testing (GREAT) program,
this quality improvement project’s results will be translated into practice with the use of the
evidence-based intervention (SCSQ) assessment as part of the hereditary screening process by
APRNs in clinical practice.
Essential 4: Information Systems or Technology and Patient Care Technology for the
Improvement and Transformation of Health Care
The use of information technology in the oncology practice setting permitted the
transmittal of study information to study participants and assisted in data organization during this
research project. The translation of research findings into evidence-based findings in high-risk
individuals undergoing hereditary cancer screening was made possible using SPSS version 20.0.
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Study limitations included a small sample size of 30 participants and the three-month study
duration. The SCSQ could essentially be incorporated into the electronic health record (EHR) as
part of the genetic packet emailed to patients during the scheduling phase. If the APRN identifies
psychosocial needs during the GCRA pretesting visit, a thorough assessment and evaluation of
needs will be completed, and appropriate psychosocial referrals will be made via the EHR
ordering system. I hope to incorporate this protocol into my clinical practice as an assessment
tool for high-risk individuals seeking hereditary screening services. In January 2022, I hope to
meet with the GREAT program director Gayle Patel, Certified Genetic Counselor (CGC), and
senior manager for clinical services for McKesson, Lori Lindsey FNP-BC, to design a protocol
utilized in all clinical sites providing GCRA services (McKesson Specialty Health supports the
U.S. Oncology Network).
Essential 5: Health Care Policy for Advocacy in Health Care
Genetics has revolutionized how cancer risk is assessed in previvors, and it also impacts
treatment decisions in patients who have a cancer diagnosis. However, numerous negative
implications and challenges are associated with hereditary cancer screening. Advanced practice
registered nurses trained in providing GCRA services should be aware of these implications and
treat the patient holistically, assessing for and addressing psychosocial concerns. Organizational
standards can be improved with the DNP’s engagement in policy development related to
standardizing psychosocial health assessments in the outpatient oncology setting for all high-risk
individuals presenting for GCRA. Promoting clinical awareness and perceptions of APRNs
involved in genetics on the psychosocial issues that are associated with GCRA can help the DNP
design and implement health care policies that promote quality of care in oncology, which can
include building a robust psychosocial referral system and a psychosocial interdisciplinary team
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for any identified high-risk individual. Early identification of psychosocial needs in this patient
population is an important starting point for a practical clinical application of genetic testing and
to organize personalized care plans, which can drive patients to self-determination of a healthy
lifestyle and to make appropriate clinical decisions for their health (Oliveri et al., 2018). On the
local and national landscape, the DNP is equipped to provide public awareness programs that
highlight the psychosocial issues related to hereditary cancer screening as it becomes more
mainstream and accessible.
Essential 6: Interprofessional Collaboration for Improving Patient and Population Health
Outcomes
Collaborative skills are essential in implementing psychosocial treatment plans that
include interprofessional practice. The APRN should address identified psychosocial needs and
appropriate clinical referrals made. The DNP plays a crucial role in establishing and leading a
network of other clinicians trained to address psychosocial concerns in this high-risk hereditary
cancer population. The DNP will also employ effective communication strategies with these
high-risk individuals, office staff, social workers, and mental health providers to provide
comprehensive and excellent patient-centered care. In implementing new practice guidelines and
standards of care in the hereditary cancer screening arena, the DNP utilizes collaborative and
communication skills with the GREAT program director and the five regional genetic counselors
who are responsible for providing educational support to all the APRNs in practice and
operational support throughout the GREAT program.
Essential 7: Clinical Prevention and Population Health for Improving the Nation’s Health
Nurses are positioned to contribute to and lead the transformative changes that are
occurring in health care by being fully contributing members of the interprofessional team as
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they shift from episodic, provider-based, fee-for-service care to team-based, patient-centered
care across the continuum that provides seamless, affordable, and quality care (Salmond &
Echevarria, 2017). In the oncology research setting, providing evidence-based data to oncology
APRNs on the clinical utility of assessing the psychosocial status of high-risk individuals
undergoing hereditary cancer screening is instrumental in promoting high-quality holistic nursing
care.
According to the RUIT theory, APRNs can help high-risk individuals manage their
uncertainty about the cause of their disease if they have cancer or if they are previvors in the
likelihood of developing cancer by helping them gain knowledge, solve problems, and perceive
health issues as manageable. Discovering the antecedents of uncertainty provides the APRN with
salient clues about the patient’s uncertainty, and the psychosocial interventions aimed at
managing uncertainty are based on understanding the individual’s view about the situation and
defining the characteristics of uncertainty (Taş Bora & Buldukoğlu, 2020). According to the
National Cancer Institute (n.d.), many individuals at risk for cancer lack access to genetic
screening and preventative approaches due to cost, geographical location, or lack of
understanding about these strategies. By improving the availability and uptake of these tests by
individuals and families at high risk for cancer, significant improvements can be made to prevent
and treat inherited cancer syndromes early (NCI, n.d.). With the shortage of trained genetic
counselors in the United States, oncology APRNs are bridging this health care gap,
implementing evidence-based strategies to identify those at risk and implementing appropriate
clinical management, which improves population health.
Health care systems are integrating cancer risk assessment services into their settings to
improve services, differentiate themselves from other practices, and provide overall better care
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for the communities they serve, and many APRNs have been asked to participate in or lead these
new initiatives (King & Smith, 2020). Psychosocial and behavioral outcomes of genetic testing
in oncology are well known, and the implementation of a clinical initiative that addresses these
concerns is vital in helping improve the overall health status of the population of the United
States.
Essential 8: Advanced Nursing Practice
The specialization and subspecialization in nursing have enabled APRNs to work in
distinctly complex areas of practice. With the expanding role of the APRN in genomic practice,
there have been two distinct pathways. First, APRNs are now offering cancer risk assessment
services in a consultative arena where the APRNs engage in risk assessment and develop a plan
of care meant to be provided by the patient’s referring provider. Secondly, other APRN-led
GCRA programs provide a more comprehensive cancer risk assessment, develop and implement
plans of care, and monitor high-risk patients long-term (King & Smith, 2020). As a nurse
practitioner in oncology who provides hereditary cancer screening services, it is essential to
explore therapeutic interventions such as assessing psychosocial status in high-risk individuals
and appropriately referring them as this is based on evidence in the literature.
Advanced practice registered nurses are adept at developing collaborative relations with
many members of the health care organization. This research project highlighted the fact that the
APRN can advance and support therapeutic partnerships with patients, their families, and other
professionals to facilitate patient outcomes and optimal care. It is efficacious that oncology
APRNs running high-risk hereditary cancer clinics collaborate through a referral system with
other APRNs in different specialties like primary care, obstetrics/gynecology, gastroenterology,
urology, dermatology, endocrinology, neurology, genetics, and nephrology with the main aim of
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improving population health outcomes. This DNP project demonstrated a systematic health
assessment in high-risk individuals and the evaluation of evidence-based care to improve these
patient outcomes in hereditary cancer screening.
Recommendations for Future Research
The assessment of psychosocial risk in high-risk individuals undergoing hereditary
cancer screening by APRNs in the community setting must be assimilated in the pregenetic
counseling visit because it can help identify patients who may need additional psychosocial
support. Given the rapid advancement of genomic medicine, understanding the evidence based
on the psychosocial impact of genomic testing is imperatively needed to help provide adequate
support in high-risk individuals. Utilizing a psychosocial screening tool such as the GPRI or
SCSQ has been shown to help identify individuals who need additional psychosocial support
services. However, this study did not reveal any significant difference in the percentage of
referrals between the two tools, and future research can be aimed at a head-to-head comparison
of the two validated screening tools used in GCRA, namely the Genetic Psychosocial Risk
Instrument (GPRI) and Psychosocial Aspects of Hereditary Cancer (PAHC) questionnaire.
Addressing these psychosocial concerns allows patients to participate in their plan of care and
make informed medical decisions and enables providers to understand the impact of
psychosocial distress during the hereditary screening process. Further nursing research is needed
to help identify specific psychosocial needs after positive hereditary cancer results disclosure.
Moreover, research that could assist in identifying specific psychosocial needs among different
family members during the GCRA process is also important to explore.
Additional research utilizing a larger sample size with an extended study duration is
essential to further improve psychosocial screening practices in different settings and establish a
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gold standard for psychosocial measurement in the hereditary screening arena. A small sample
size can affect the reliability and variability, which may lead to bias. Larger sample sizes have
been shown to provide more accurate mean values and identify outliers that could skew the data.
The variability of utilizing different clinical settings that offer hereditary cancer screening
ranging from outpatient, inpatient, urban, rural, and teaching hospitals can significantly
strengthen the assessment of psychosocial risk factors in the broader variation of these high-risk
individuals. Additionally, future studies could highlight the long-term psychosocial impact of the
hereditary cancer screening process by utilizing a prospective, longitudinal study design. Also,
psychosocial assessments during the posttesting phase can provide information about the
changes in knowledge, cancer worries, distress, and risk perception. Advanced practice
registered nurses could enhance their high-risk hereditary cancer clinics by improving their
psychosocial screening practices by creating an interdisciplinary network that addresses any
identified psychosocial needs.
Conclusion
It has been shown that psychosocial challenges can transpire throughout the hereditary
cancer screening process, ranging from discussions about referrals for testing to medical
decisions based on results. This project evaluated the need for psychosocial screening services
utilizing a psychosocial assessment tool in high-risk individuals undergoing GCRA by oncology
APRNs in the community setting. This study’s findings ascertained that a certain percentage of
the study participants experienced heightened anxiety, depression, guilt, worry about disease risk
and passing down genes to their children, fear about illness if positive, relationship worries, or
distress during the GCRA process. Thus, it is indispensable to systematically evaluate and detail
the psychosocial variables during the GCRA process and appropriately refer these patients for
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psychosocial interventions. The study’s findings also revealed that the use of the SCSQ
identified one patient more who needed a psychosocial referral compared to the GPRI. However,
it is important to note that not all study participants accepted psychosocial referrals even when a
need was identified. Thus, there was no statistically significant association between referral and
assessment tools, and the null hypothesis could not be rejected. There was also an overall
improvement in the number of study participants referred for additional psychosocial support
during this study.
The findings revealed that psychosocial risk assessments needed to be assessed at the
precounseling and postcounseling phases of the GCRA, and a viable psychosocial risk
assessment tool are critical to implementing routinely. It is imperative to assess the high-risk
individual’s perception of their psychosocial needs associated with the hereditary screening
process, refer them appropriately, and provide them information on the availability of these
services. The dissemination of this evidence-based research project can help APRNs tailor the
way they deliver genetic and genomic information and holistically address any psychosocial
concerns that may arise during the hereditary screening process. It can also assist in changing
current clinical practice by improving health outcomes and patient care. Dissemination of this
evidence should not be limited to [redacted] only but should be shared nationally and with the
public to help address the psychosocial issues that arise during the hereditary cancer screening
process.
Precision medicine calls for APRNs involved in genetic and genomics to tailor medical
treatment based on each patients’ individual characteristics, and aside from performing a nursing
assessment, identify hereditary risk, provide patient counseling, order testing, interpret testing,
and make appropriate clinical recommendations, the APRN should provide additional
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psychosocial support as needed. The pathways to disseminate this evidence-based research
include presenting this study’s findings in oncology nursing journals, roundtable discussions, and
oral presentations. Diversification of oncology nurse practitioner practice to include GCRA has
resulted from the limited number of adequately trained health care providers, time constraints of
busy practicing clinicians, and failure to obtain and update family cancer history. The emergence
of alternate practice models that have evolved to extend these genetic cancer risk assessment
services outside of the traditional academic genetics model into a community-based approach
using APRNs has been successful (King & Smith, 2020). Doctors of Nursing Practice trained in
genetics are called to fulfill the demands of the high-risk population undergoing hereditary
cancer screening as they are equipped with advanced assessment skills and can view the highrisk individuals holistically while tailoring individualized care plans. The APRNs also have
higher educational training in interdisciplinary collaboration, leadership, and evidence-based
practice as they can continually adapt to the rapidly evolving world of clinical genetics.
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